Distribution of the first recombinant Factor VIII from human cells

The distribution in Italy of human cell-derived recombinant Factor VIII manufactured by Octapharma AG for the next ten years is the subject of an agreement signed between Kedrion, the Italian leader in plasma-derived products, and Octapharma AG. The product’s indication is the treatment of Haemophilia A, a condition that according to estimates affects over three thousand people in Italy, with an estimated requirement of over 400 million units of recombinant and plasma-derived Factor VIII.

The agreement was signed on 21st October after Octapharma had announced that it had started the European marketing authorisation procedure for the medicinal product and had submitted it to EMA, the European Medicines Agency.

With such agreement, Kedrion upgrades its efforts for the development of treatments for haemophilic patients, an area in which the company is already working as the manufacturer and distributor of plasma-derived Factor VIII from Italian volunteer donors’ plasma.

For more information please contact: [email protected]
error: Content is protected !!